Hypertension. Essential (primary) hypertension
Conditions
Interventions
Intervention 1: Intervention group: Vitamin D at a dose of 50000 international units of six supplements, one supplement for week and then two supplements, one for monthly, by Zahravi Tabriz Company, t
Sponsors
Oroumia University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age range 18 years and above Interested in attending a study that filled out an informed consent form Hypertensive patients with systolic blood pressure above 140 and diastolic blood pressure above 90 with identical conditions and approved by the cardiologist in the study Serum vitamin D levels less than 30 ng/dl People who use only the following four drugs to control their blood pressure1Angiotensin Inhibitors (Losartan, Captopril, Valsartan)2 Calcium channel blockers (amlodipine, diltiazem)3Inhibitors of beta-adrenergic receptors (ethnolol, metoprolol, bisoprolol (concur))4Diuretics (hydrochlorothiazide, triamterene)
Exclusion criteria
Exclusion criteria: Mental, emotional, cognitive disorders People under 18 years People with secondary hypertension Specific dietary restrictions Pregnant women Nonsteroidal anti-Inflammatory drugs or glucocorticoids Disease that requires chemotherapy or radiation Consumption of bisphosphonates, including alendronate, alendronate and rhizdronate Use of anticonvulsant drugs (including phenytoin, phenobarbital, primidone, carbamazepine, x carbazepine, valproic acid, clonazepam) Use of antihyperlipidemic diarrhea medications including cholestyramine Alcohol consumption Consumption of radioactive iodine or any radiation Oral or injectable corticosteroids (including prednisone, prednisilone, dexamethasone, triaxinolone, hydrocortisone or beta-metazone) Kidney diseases Calcium supplements Lactating women Coeliac disease Crohn's disease Ulcerative colitis Steatorrhea Biliary problems Potassium supplementation Magnesium Supplementation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stages of blood pressure. Timepoint: at baseline (before intervention) and end of study (after 14 weeks). Method of measurement: Ambulatory Blood Pressure Monitoring, millimeter mercury. | — |
Secondary
| Measure | Time frame |
|---|---|
| Vitamin D from daily diet. Timepoint: At the beginning of the study (before the intervention) and at 6 and 10 weeks and at the end of the study (after 14 weeks). Method of measurement: Food Frequency Questionnaire.;Duration of exposure to sunlight. Timepoint: At the beginning of the study (before the intervention) and at 6 and 10 weeks and at the end of the study (after 14 weeks). Method of measurement: Sun Exposure Questionnaire.;The amount of physical activity. Timepoint: At the beginning of the study (before the intervention) and at 6 and 10 weeks and at the end of the study (after 14 weeks). Method of measurement: International Physical Activity Questionnaire.;Weight. Timepoint: At the beginning of the study (before the intervention) and at 6 and 10 weeks and at the end of the study (after 14 weeks). Method of measurement: Weigh measuring scales with accuracy of 0.1 ± mg, kilogram.;Waist circumference. Timepoint: At the beginning of the study (before the intervention) and at 6 and 10 weeks and at the end of the study (after 14 weeks). Method of measurement: Meter 0.1 centimetre precision.;Serum vitamin D levels. Timepoint: At the beginning of the study (before the intervention) and at the end of the study (after 14 weeks). Method of measurement: Enzymatic method with auto analysis, nano molar per liter. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSamira Faraji
Oroumia University of Medical Sciences
Outcome results
None listed